

Australian Technical Advisory Group on Immunisation (ATAGI) 60th Meeting - June 2016

Agenda – Day 1

Item	Purpose
1.0 Welcome and Apologies and general committee business	
1.1 Conflict of Interest and Confidentiality	Information
1.2 Actions arising from previous meeting	Information
1.3 Out of session items including correspondence	Information
2.0 Recap on Industry Day	Discussion
3.0 Influenza vaccine	
3.1 Endorse advice on influenza vaccine for submission to Pharmaceutical Benefits Advisory Committee (PBAC)	Endorse
3.2 Discussion of Influenza Industry Briefing Presented on 15 June 2016	Discussion
4.0 Pneumococcal vaccine	
4.1 Membership of Pneumococcal Working Party and Conflict of Interest (Col) Review Process	Note
4.2 Endorse Advice on Pneumococcal Vaccine for Post Submission Advice to PBAC	Endorse
4.3 Endorse the principal positions for updated evidence-based recommendations of pneumococcal vaccine use for younger Aboriginal and Torres Strait Islander adults	Endorse

5. Pertussis Vaccine

5.1 Review Terms of Reference of Pertussis Working Party and Col Process	Endorse
--	---------

5.2 Endorse Advice on a pertussis-containing vaccine for Post Submission Advice to PBAC	Endorse
---	---------

6.0 Department / Committees' Updates

6.1 Department of Health Update	Information
---------------------------------	-------------

6.2 Therapeutic Goods Administration / Advisory Committee on the Safety of Vaccines (TGA/ACSOV) Update	Information
--	-------------

6.3 Report on Previous and Upcoming Pharmaceutical Benefits Advisory Committee Meetings	Discussion
---	------------

6.4 Communicable Diseases Network Australia (CDNA) Report and Epidemiology of Vaccine Preventable Diseases	Information
--	-------------

9.0 BCG Supply	Discussion
----------------	------------

8.0 NCIRS Report	Information
------------------	-------------

Meeting closed

Agenda – Day 2

Agenda item

Recap of day one

PBAC advice for Pneumococcal, Influenza and Pertussis Vaccines	Endorse
--	---------

10.0) Australian Immunisation Handbook	
10.1) Discussion of 2017 Handbook Update	Discuss
10.2) Report of the Australian Immunisation Handbook Working Party	Discuss
11.0) ATAGI Strategic Directions	
12.0) Report from other Working Parties	
12.1) HPV Working Party – Review of updated epidemiology of HPV disease in Australia ¹	Endorse
12.2) Special Risk Groups Working Party – Membership and Terms of Reference	Endorse
12.3) Meningococcal W joint Working Group with CDNA	Information
13.0 Report from Chair and Members on ATAGI Business	
13.1 WA Mumps workshop	Discuss
13.2 Report on International meeting of National Immunization Technical Groups, Annecy, May 2016	Information
13.3) ATAGI Work Plan	Information
	Information
7.0 Australian Institute of Health and Welfare (AIHW) Presentation on Burden of Vaccines-Preventable Diseases (VPDs)	
14.0) Other Business	Discuss
Meeting closed	

Endorse = a decision is to be made at this meeting

Discussion = a decision is to be made at a future meeting or out of session

Information = no decision points at this stage

1. This item will also cover presentation of preliminary summary information of 2-dose studies of the 9 valent HPV vaccine, however, it is not possible to publish this.